Patrick Hwu: Could a Probiotic Help More People with Colorectal Cancer Benefit from Immunotherapy?
Patrick Hwu, President and CEO of the Moffitt Cancer Center, shared a post on LinkedIn about recent paper published in Cancer Cell:
“Could a probiotic help more people with colorectal cancer benefit from immunotherapy?
A new study in Cancer Cell found that the probiotic Clostridium butyricum can enhance the effects of anti–PD-1 therapy in colorectal cancer models. It worked by boosting the number and activity of cancer-fighting CD8⁺ T cells and reducing immune-suppressing tumor-associated macrophages.
Researchers at The Chinese University of Hong Kong discovered that a protein on the probiotic’s surface binds to a receptor on tumor cells, switching off signals that promote inflammation and tumor growth. The probiotic also produced butyrate, a beneficial metabolite that further improved immune responses.
Tested in multiple lab and animal models, including patient-derived tumor–immune cell co-cultures, this approach could be developed as an add-on to make immunotherapy more effective for colorectal cancer.”
Title: Tumor-resident probiotic Clostridium butyricum improves aPD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression
Authors: Mingxu Xie, Kai Yuan, Yongxin Zhang, Yating Zhang, Ruyi Zhang, Jiuhe Gao, Wenchao Wei, Lanping Jiang, Tianhui Li, Yanqiang Ding, Luyao Wang, Yufeng Lin, Chi Chun Wong, Jun Yu
Read The Full Article at Cancer Cell.
More posts featuring Patrick Hwu on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023